Reviva Pharmaceuticals Holdings (RVPH) Other Non-Current Liabilities (2021 - 2025)
Reviva Pharmaceuticals Holdings (RVPH) posted Other Non-Current Liabilities of $44506.0 for Q3 2025, up 166.66% sequentially from $16690.0 in Q2 2025, and down 42.86% YoY from $77884.0 in Q3 2024.
Reviva Pharmaceuticals Holdings (RVPH) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Other Non-Current Liabilities for 5 years, with the latest figure at $44506.0 in Q3 2025.
- Quarterly Other Non-Current Liabilities fell 42.86% year-over-year to $44506.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $44506.0 (down 42.86% YoY) and the FY2024 annual result came in at $89010.0, down 88.97% from the prior year.
- Other Non-Current Liabilities grew to $44506.0 in Q3 2025 per RVPH's latest filing, from $16690.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.0 million in Q1 2021 and troughed at $16690.0 in Q2 2025.
- A 5-year average of $422798.1 and a median of $317099.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities jumped 857.9% in 2023, then plunged 92.06% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $650886.0 in 2021, then retreated by 12.82% to $567439.0 in 2022, then soared by 42.16% to $806655.0 in 2023, then sank by 88.97% to $89010.0 in 2024, then tumbled by 50.0% to $44506.0 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $44506.0, $16690.0, and $27816.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 44,506.00 |
| Jun 30, 2025 | 16,690.00 |
| Mar 31, 2025 | 27,816.00 |
| Dec 31, 2024 | 89,010.00 |
| Sep 30, 2024 | 77,884.00 |
| Jun 30, 2024 | 150,205.00 |
| Mar 31, 2024 | 350,478.00 |
| Dec 31, 2023 | 806,655.00 |
| Sep 30, 2023 | 873,411.00 |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 556,313.00 |
| Dec 31, 2022 | 567,439.00 |
| Sep 30, 2022 | 105,699.00 |
| Jun 30, 2022 | 105,699.00 |
| Mar 31, 2022 | 283,720.00 |
| Sep 30, 2021 | 650,886.00 |
| Jun 30, 2021 | 851,160.00 |
| Mar 31, 2021 | 1.04 Mn |